Is Eiko Lifescience overvalued or undervalued?

As of 1 July 2025, Eiko Lifescience's valuation grade has moved from expensive to fair, indicating a shift in market perception. The company is currently assessed as fairly valued. Key ratios include a PE ratio of 46.11, an EV to EBITDA of 34.27, and a PEG ratio of 0.68, which suggests that while the company may appear pricey on a PE basis, its growth potential is being recognized through the lower PEG ratio.
In comparison to its peers, Eiko Lifescience's PE ratio is significantly higher than that of Life Insurance, which stands at 12.71, and IRFC, which has a PE of 28.43. This highlights that while Eiko is fairly valued, it remains more expensive than several competitors in the specialty chemicals sector. The company's recent stock performance has lagged behind the Sensex, particularly in the year-to-date return, where it has declined by 20.61% compared to the Sensex's gain of 7.11%.